全文获取类型
收费全文 | 32635篇 |
免费 | 4286篇 |
国内免费 | 397篇 |
专业分类
耳鼻咽喉 | 988篇 |
儿科学 | 825篇 |
妇产科学 | 814篇 |
基础医学 | 3468篇 |
口腔科学 | 855篇 |
临床医学 | 3833篇 |
内科学 | 6894篇 |
皮肤病学 | 1018篇 |
神经病学 | 3229篇 |
特种医学 | 1327篇 |
外科学 | 5797篇 |
综合类 | 229篇 |
现状与发展 | 2篇 |
一般理论 | 11篇 |
预防医学 | 2414篇 |
眼科学 | 924篇 |
药学 | 1767篇 |
中国医学 | 187篇 |
肿瘤学 | 2736篇 |
出版年
2023年 | 659篇 |
2022年 | 238篇 |
2021年 | 1100篇 |
2020年 | 1159篇 |
2019年 | 855篇 |
2018年 | 1459篇 |
2017年 | 1185篇 |
2016年 | 1445篇 |
2015年 | 1540篇 |
2014年 | 2019篇 |
2013年 | 2451篇 |
2012年 | 2429篇 |
2011年 | 2231篇 |
2010年 | 1697篇 |
2009年 | 1762篇 |
2008年 | 1630篇 |
2007年 | 1537篇 |
2006年 | 1574篇 |
2005年 | 1323篇 |
2004年 | 1126篇 |
2003年 | 920篇 |
2002年 | 856篇 |
2001年 | 581篇 |
2000年 | 466篇 |
1999年 | 456篇 |
1998年 | 405篇 |
1997年 | 358篇 |
1996年 | 381篇 |
1995年 | 365篇 |
1994年 | 252篇 |
1993年 | 191篇 |
1992年 | 262篇 |
1991年 | 228篇 |
1990年 | 167篇 |
1989年 | 226篇 |
1988年 | 177篇 |
1987年 | 143篇 |
1986年 | 155篇 |
1985年 | 147篇 |
1984年 | 125篇 |
1983年 | 115篇 |
1982年 | 106篇 |
1981年 | 66篇 |
1980年 | 81篇 |
1979年 | 45篇 |
1978年 | 67篇 |
1977年 | 66篇 |
1976年 | 46篇 |
1975年 | 63篇 |
1974年 | 41篇 |
排序方式: 共有10000条查询结果,搜索用时 703 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
Sung‐Hyun Hwang Myung‐Chul Kim Sumin Ji Yeseul Yang Yeji Jeong Yongbaek Kim 《Cancer science》2019,110(4):1256-1267
Metformin, a drug for type 2 diabetes mellitus, has shown therapeutic effects for various cancers. However, it had no beneficial effects on the survival rate of human malignant mesothelioma (HMM) patients. The present study was performed to elucidate the underlying mechanism of metformin resistance in HMM cells. Glucose‐starved HMM cells had enhanced resistance to metformin, demonstrated by decreased apoptosis and autophagy and increased cell survival. These cells showed abnormalities in mitochondria, such as decreased ATP synthesis, morphological elongation, altered mitochondrial permeability transition pore and hyperpolarization of mitochondrial membrane potential (MMP). Intriguingly, Mdr1 was significantly upregulated in mitochondria but not in cell membrane. The upregulated mitochondrial Mdr1 was reversed by treatment with carbonyl cyanide m‐chlorophenyl hydrazone, an MMP depolarization inducer. Furthermore, apoptosis and autophagy were increased in multidrug resistance protein 1 knockout HMM cells cultured under glucose starvation with metformin treatment. The data suggest that mitochondrial Mdr1 plays a critical role in the chemoresistance to metformin in HMM cells, which could be a potential target for improving its therapeutic efficacy. 相似文献
5.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
6.
7.
Anne E. Kazak Fang Fang Chen Wei‐Ting Hwang Martha A. Askins Gabriela Vega E. Anders Kolb Anne Reilly Lamia P. Barakat 《Pediatric blood & cancer》2020,67(2)
Purpose: Family psychosocial risk in pediatric oncology can be assessed using the Psychosocial Assessment Tool (PAT), a brief parent report screener based on the Pediatric Psychosocial Preventative Health Model (PPPHM; universal, targeted, and clinical). However, little is known about risk over the course of treatment and its association with medical and psychosocial healthcare utilization. Methods: Primary caregivers of children with cancer participated in this prospective multisite investigation, completing the PAT at diagnosis (T1; n = 396) and 6 months later (T2; n = 304). Healthcare utilization data were extracted from electronic health records. Results: The distribution of PPPHM risk levels at T1 and T2 was highly consistent for the samples. Two‐thirds of families remained at the same level of risk, 18% decreased and 16% increased risk level. Risk was not related to sociodemographic or treatment variables. The PAT risk score correlated with psychosocial contacts over the 6‐month period. Conclusions: Although the majority of families reported universal (low) risk on the PAT and were stable in their risk level over 6 months, reassessing risk is helpful in identifying those families who report higher level of risk during treatment than at diagnosis. PAT scores were related to psychosocial services that are provided to most but not all families and could be tailored more specifically to match risk and delivery of evidence‐based care. 相似文献
8.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 下载免费PDF全文
9.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献